Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HitGenSHSE:688222 -4.72%90 Days Inventory is 58.76 as of Mar. 2026, which is 15% below its 10-year median of 69.13. GuruFocus rates SHSE:688222 with a GF Score™ of 90/100 and a GF Value™ of ¥26.11 (Fairly Valued). The stock has 1 warning sign investors should review. Among 637 Biotechnology companies, HitGen ranks better than 83.99% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). HitGen's Average Total Inventories for the
three
months ended in Mar. 2026 was ¥45.1 Mil. HitGen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ¥70.1 Mil.
Hence, HitGen's Days Inventory for the
three
months ended in Mar. 2026 was 58.76.
The historical rank and industry rank for HitGen's Days Inventory or its related term are showing as below:
SHSE:688222'
s Days Inventory Range Over the Past 10 Years
Min: 51.76 Med: 69.13 Max: 169.13
Current: 58.26
During the past 10 years, HitGen's highest Days Inventory was 169.13. The lowest was 51.76. And the median was 69.13.
SHSE:688222's Days Inventory is ranked better than 83.99% of 637
companies
in the Biotechnology industry
Industry Median: 183.16
vs SHSE:688222: 58.26
HitGen's Days Inventory
declined
from Mar. 2025 (62.00) to Mar. 2026 (58.76).
Inventory Turnover measures how fast the company turns over its inventory within a year.
HitGen's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.55.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
HitGen's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.28.
HitGen (SHSE:688222) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
HitGen's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
HitGen's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
HitGen Days Inventory Related Terms
HitGen Days Inventory Historical Data
* Premium members only.
The historical data trend for HitGen's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688222 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, HitGen's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HitGen Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HitGen's Days Inventory distribution charts can be found below:
* The bar in red indicates where HitGen's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HitGen (SHSE:688222) has a Days Inventory of 58.76 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on HitGen and its competitors. This is 15% below median its historical median of 69.13. Over the past decade, HitGen's Days Inventory has ranged from 51.76 to 169.13. According to the industry distribution chart, HitGen ranks #102 out of 637 companies in the Biotechnology industry, placing it in the top 16%.
Is HitGen's Days Inventory too high?
HitGen's current Days Inventory of 58.76 is 15% below median its 10-year median of 69.13. Over the past 10 years, this metric has ranged from a low of 51.76 to a high of 169.13. The Biotechnology industry median Days Inventory is 183.16. HitGen's value of 58.76 is 67.9% below this industry median. Based on the distribution chart, HitGen ranks #102 out of 637 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HitGen has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HitGen's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HitGen ranks #102 out of 637 companies for Days Inventory. This places HitGen in the top 16% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.16. HitGen's value of 58.76 is 67.9% below this benchmark. Historically, HitGen's own Days Inventory has ranged from 51.76 to 169.13 over the past decade. While the company's 10-year median is 69.13 vs. the industry median of 183.16, HitGen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.16, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HitGen's current Days Inventory of 58.76 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on HitGen and its competitors. For the Biotechnology industry, the median Days Inventory is 183.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HitGen's current Days Inventory is 58.76, which is 15% below median its own 10-year median of 69.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HitGen stock overvalued right now?
Based on GuruFocus' analysis, HitGen (SHSE:688222) is currently considered Fairly Valued. The stock's GF Value™ is ¥26.11, compared to a current price of ¥28.26 — trading 8.2% above its estimated fair value. The current Days Inventory is 58.76, which is 15% below median its 10-year median of 69.13 and 67.9% below the Biotechnology industry median of 183.16. HitGen's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For HitGen (SHSE:688222), the current Days Inventory is 58.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HitGen (SHSE:688222) Overvalued in 2026?
Based on GuruFocus' analysis, HitGen stock appears to be overvalued.
The current stock price of ¥28.26 is trading 8.2% above its estimated GF Value™ of ¥26.11.
GuruFocus considers HitGen to be Fairly Valued.
Key valuation signals for SHSE:688222:
Days Inventory: 58.76 (15% below median its 10-year median of 69.13)
GF Value™: ¥26.11 vs. price of ¥28.26 (8.2% above fair value)
Industry Position: 67.9% below the Biotechnology median (#102 of 637)
No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
90GF Score
Get the complete analysis for SHSE:688222
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688222 has been successfully added to your 
